Impact of New Drugs and Biologics on Colorectal Cancer Treatment and Costs

Abstract

Purpose: To compare medical expenditures of patients receiving old and new colorectal cancer (CRC) regimens.

Medical Costs Associated with Use of Systemic Therapy in Adults with Colorectal Cancer

“…12 Until recently, 3 regimens dominated firstline treatment of CRC: FU, available since the 1960s, which has been routinely administered with FU/LV since the early 1990s or with irinotecan (IFL or Folfiri) since 2000. 8,13,14 In the past decade, the U.S. Food and Drug Administration approved several new drugs, such as capecitabine, oxaliplatin, bevacuzimab, cetuximab, and panitumumab, which have been widely used in the treatment of CRC patients. 8 This study found that biologics, including bevacuzimab, cetuximab, and panitumumab, were more likely added into regimens in the third + lines as compared with earlier lines.…”

“…8,13,14 In the past decade, the U.S. Food and Drug Administration approved several new drugs, such as capecitabine, oxaliplatin, bevacuzimab, cetuximab, and panitumumab, which have been widely used in the treatment of CRC patients. 8 This study found that biologics, including bevacuzimab, cetuximab, and panitumumab, were more likely added into regimens in the third + lines as compared with earlier lines.…”

“…8 Clinical studies indicate that bevacizumab in combination with 5-fluorouracil/leucovorin (FU/LV) and bevacizumab in combination with irinotecan plus FU/LV (Folfiri) are clinically more effective in comparison with standard chemotherapy options for the first-line treatment of metastatic CRC. 9 However, these expanded options have increased treatment costs and, in some cases, toxicity.…”

Repurposing of Modified Alpidem and Propoxyphene to Cure AURKA, BCAS1, GNAS and MLH1 Gene Mutations in Colorectal Cancer

“…These new biologic operators-bevacizumab, cetuximab, and panitumumabare regularly alluded to as monoclonal antibodies. In fact; these antibodies encourage immune responses against quickly multiplying cancer cells [19]. Drug repurposing has several advantages and the endeavors have been driven by a few imperative components including; the access to expanding measures of experimental information, better comprehension of compound poly pharmacology and biological information mining.…”

The High Cost of Cancer Drugs and What We Can Do About It

“…29 However, the costs of health care are not increasing only in pharmaceuticals but in many areas, including hospitalizations and imaging. 30,31 In addition, many pharmaceutical companies have been generous in providing medications at low or no cost to qualifying patients. The cost of care is a systemwide problem that includes many participants, including health care professionals, device manufacturers, and medical supply manufacturers.…”